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Abstract
Background: Data from the US indicates that methadone-maintained populations are aging, with an increase of
patients aged 50 or older. Data from European methadone populations is sparse. This retrospective cohort study
sought to evaluate the age trends and related developments in the methadone population of Basel-City,
Switzerland.
Methods: The study included methadone patients between April 1, 1995 and March 31, 2003. Anonymized data
was taken from the methadone register of Basel-City. For analysis of age distributions, patient samples were split
into four age categories from ‘20-29 years’ to ‘50 years and over’. Cross-sectional comparisons were performed
using patient samples of 1996 and 2003.
Results: Analysis showed a significant increase in older patients between 1996 and 2003 (p < 0.001). During that
period, the percentage of patients aged 50 and over rose almost tenfold, while the proportion of patients aged
under 30 dropped significantly from 52.8% to 12.3%. The average methadone dose (p < 0.001) and the 1-year
retention rate (p < 0.001) also increased significantly.
Conclusions: Findings point to clear trends in aging of methadone patients in Basel-City which are comparable,
although less pronounced, to developments among US methadone populations. Many unanswered questions on
medical, psychosocial and health economic consequences remain as the needs of older patients have not yet
been evaluated extensively. However, older methadone patients, just as any other patients, should be accorded
treatment appropriate to their medical condition and needs. Particular attention should be paid to adequate
solutions for persons in need of care.
Background
The prevalence of opioid dependence is relatively stable
in most European countries, including Switzerland, and
currently stands at 0.1%-0.8% [1,2]. Opioid dependence
is a serious chronic condition that comes with a multi-
tude of health and psychosocial risks and one which
requires adequate long-term treatment [3-5]. Based on
decades of research, maintenance treatment with metha-
done or other suitable opioids, such as buprenorphine
and slow-release morphine, is currently the mainstay of
therapy for opioid dependence [6-8]. Opioid mainte-
nance is effective, well-tolerated and internationally
accepted; it is also one of the most widely studied
treatments for any disease [5,9,10]. Given adequate
dosage and regular dosing, maintenance medication can
prevent withdrawal symptoms, curb craving for heroin
as well as other opioids and block their rewarding
effects [8,11,12]. Maintenance treatment also substan-
tially reduces health and psychosocial risks associated
with illicit opioid use [13-15]. Ideally, it would be a
comprehensive treatment integrating medical care, psy-
chosocial counselling and other services in which main-
tenance medication is prescribed to opioid-dependent
persons without any undue restrictions [16,17].
Since its inception over 45 years ago, hundreds of
thousands of opioid users worldwide have benefited
from methadone maintenance [5,7]. While a new gen-
eration of opioid-dependent persons is entering treat-
ment for the first time, at the other end of the age
spectrum the population of older long-term patients
continues to grow rapidly [18-21]. This is largely due to
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the success of methadone programs in retaining patients
in treatment and helping to prolong their lives–all that
in spite of often complex and comorbid cases
[20,22-25]. Furthermore, Arndt et al. recently found
increasing proportions of patients aged older than 55
mentioning problematic heroin use when presenting for
first-time treatment of substance use in the US [26].
There are many references in geriatric literature to
methadone as it relates to the management of chronic
and cancer pain. However, little information is available
about opioid use and maintenance treatment in the
elderly as well as their specific needs [20,24,25]. In addi-
tion, virtually no research addresses developments of the
age structure of methadone populations. Among the
exceptions are reports from the Addiction Treatment
Forum. Data from “Beth Israel Healthcare System”, New
York City–the largest methadone program in the US
with over 6,000 patients–points to remarkable trends
and developments in the years between 1975 and 2002
[27]. The proportion of patients aged 50 or over signifi-
cantly increased during the 27-year period to encompass
more than one third (35.3%) of patients in 2002. Nearly
6.5% were 60 or older. During the same time, the pro-
portion of patients aged 39 and under steadily declined.
Data from other methadone centers in the US show
comparable figures. According to the US Department of
Health and Human Services [21], almost 10% of metha-
done patients were over the age of 50 at the end of the
last decade, and more than 33% were between the ages
of 40 and 49. While this data points to clear trends in
aging methadone patients in the US, there is great varia-
bility across treatment centers. In a survey among ten
methadone programs from nine states, estimates of the
percentage of patients aged 55 or older ranged from 2%
to 60% [18]. This raises the questions of why the discre-
pancy exists and whether these developments are
restricted to the US or whether there are similar trends
in other countries with relatively long traditions of
methadone maintenance and rather high prevalence
rates of opioid dependence. Slowly, these issues also
attract attention in Europe, as demonstrated by the crea-
tion of collaborative projects like “SDDCare” to explore
needs and establish treatment guidelines for senior drug
users http://www.sddcare.eu.
In Switzerland, the prescription of methadone for
opioid dependence has been regulated by federal and
state laws since 1975. Methadone maintenance treatment
(MMT) is covered by health insurance and is provided by
specialized clinics and office-based practitioners author-
ized to perform this treatment [28]. It is available for
opioid-dependent individuals (according to ICD-10 cri-
teria) aged 18 years or older who show opioid use on tox-
icology screening but are not able or willing to undergo
abstinence-oriented treatment. Patients are generally free
to choose their physician and treatment is covered by
mandatory health insurance. Swiss health authorities sub-
stantially increased treatment programs in response to
open drug scenes in several cities in the beginning of the
1990s [29]. Since then, there have been sufficient facilities
for all patients willing to enter treatment. Thus, the
threshold for entrance into MMT is low, with no further
prerequisites other than opioid dependence. The name of
every patient is reported to the local health authorities
upon admission to MMT. Long-term abstinence is not
an obligatory treatment goal and there are no restrictions
regarding duration of treatment and dosing of metha-
done although currently a minimum dose of 60-80 mg/d
is recommended [30]. Take-home dosages are often
allowed for a maximum of one week. In March 2003,
about 17,000 patients were on MMT throughout Switzer-
land [29]. From these, 958 were treated in Basel-City
where the ratio of MMT patients to population has been
roughly 0.5% since 1995. The MMT population of Basel
has similar incidence trends, mean age and age of onset
of heroin use as those of other cities in Switzerland [31].
We therefore assume the cohort to be representative for
other Swiss cities.
This retrospective register-based cohort study sought
to determine the age trends in the MMT population of
Basel-City, Switzerland from April 1, 1995 to March 31,
2003, and to discuss some aspects of the potential con-
sequences related to these developments in the future.
Methods
Data basis and statistics
All data was taken from the methadone register of the
health authorities of Basel-City, the operation of which
was discontinued in 2004. MMT data in the canton of
Basel-City had been collected and evaluated since 1995.
The data collection and evaluation are in accordance
with the data protection law of the canton of Basel-City
and were approved by the local ethics committee. As
stipulated by legislation, prescribing treatment providers
in Basel-City are required to submit a registration form
to the health authorities each time a patient begins and
ends MMT. The form collects a limited amount of
information about methadone patients and their treat-
ment but provides a population-based data source
recording the duration of treatment episodes as well as
the characteristics of the prescribing provider. For moni-
toring purposes, methadone prescribers were further
invited until 2004 to provide anonymized patient and
treatment data to the register every 12 months by
means of a 2-page questionnaire. This structured ques-
tionnaire contained a core of unchanging questions
about sex, marital status, type of housing, educational
level, work situation, and self-reported substance use
during the previous 30 days.
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The present evaluation includes data of MMT patients
from April 1, 1995 to March 31, 2003. Throughout that
period, three clinics (two public, one private) and a
maximum of 81 office-based practitioners conducted
MMT in Basel-City. All returned questionnaires were
checked for plausibility and erroneous data entries were
corrected or removed if they were ambiguous. There-
fore, and since not all respondents answered all ques-
tionnaire items patient numbers vary across variables.
For the analysis of the developments in age structure,
patient samples of the years 1996, 1997, 1998, 2000,
2001, 2002 and 2003 were split into four age categories:
20-29 years; 30-39 years; 40-49 years; and 50 years and
over. Because the database for 1999 was incomplete, it
was excluded. Cross-sectional comparisons were per-
formed using patient samples of 1996 and 2003.
Statistical analysis was conducted using SPSS for Win-
dows (release 15). Data were analyzed by chi-squared
statistics, Student’s t-test for unpaired samples, and ana-
lysis of variance, where appropriate. Because of multiple
testing all statistical data were considered significant at
p < 0.01.
Results
The analysis of methadone treatments in Basel-City
indicates a clear trend in age development of the MMT
population, as depicted in Figure 1. It shows a
significant increase in older patients between 1996 and
2003. During that period, percentages of persons aged
50 and over rose tenfold from 0.4% in 1996 to 4.6% in
2003 (see Table 1). During the same period, the propor-
tion of patients aged 29 and under dropped significantly
from 52.8% in 1996 to 12.3% in 2003. This trend is
reflected in the average age of patients, which stood at
30.3 years in 1996 and rose to an average of 38.0 years
in 2003.
As shown in Table 1 the comparison of the patient
samples of 1996 and 2003 reveals further trends as well
as certain constants. The ratio of male to female
patients remained virtually unchanged, whereas the pro-
portion of employed patients working in jobs or receiv-
ing unemployment insurance payments dropped
significantly from 48.9% to 24.1%. In the same period,
the percentage of patients receiving a disability pension
increased significantly, but the educational level also
rose, overall, with more patients completing an appren-
ticeship or a higher education qualification. The 1-year
retention rate in MMT improved greatly from 65.4% to
86.9% during this period. Similarly, data from 2003
shows an average methadone dose of 80.9 mg/d while
the average methadone dose in 1996 was significantly
lower, lying in the middle of the minimum effective
dose range (60-80 mg). Of the 958 patients registered
on March, 31, 2003, 458 persons had been on MMT
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Figure 1 Age trends of the MMT population in the canton of Basel-City, Switzerland, 1996 to 2003.
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continuously since 1995 or before. This amounts to
almost half the 2003 sample (47.8%) while the overall
number of MMT patients decreased by 19.8% over the
observation period.
The data indicates that as this population ages, there
is still a high rate of illicit substance use, with many
patients using heroin and/or cocaine during the previous
month (see Table 1). In 1996, 74.5% of the population
reported using heroin during the preceding month while
in 2003, 47.1% reported past-month heroin use. In con-
trast, the prevalence of self-reported cocaine use in the
past month rose significantly from 36.5% in 1996 to
49.6% in 2003. Data from 1996 and 2003 show that
patients aged 40 and older tended to report previous-
month heroin use less often than younger patients
(1996: 64.2 vs 75.4%, Chi2[1] = 4.08, p = 0.043; 2003:
42.2 vs 50.4%, Chi2[1] = 3.87, p = 0.049) while this was
not the case for past-month cocaine use which did not
differ according to age.
Discussion
To our knowledge, this is the first register-based study
addressing age trends among a MMT population in Eur-
ope. The results show a significant increase in both
mean age and proportion aged 40 and older in MMT
patients of Basel-City between 1996 and 2003. This
trend is comparable to findings obtained in the US
[18,21,27], although there have not been many of those
and the present trends are less pronounced. The
increase in age-coupled with a relatively stable preva-
lence of opioid dependence-corresponds well with the
declining incidence of heroin use and the higher MMT
retention rates in Switzerland [1,32]. The 1-year reten-
tion rate of 86.9% in 2003 is certainly favorable [33-35].
It reached a level of 65.4% as early as 1996, which com-
pares well with national and international levels at that
time [36-39]. Taking into account other factors (e.g.
improved clinical experiences, more adequate treatment
of comorbid disorders) this increase could be due to a
less restrictive MMT practice and the prescription of
more effective methadone doses [33]. This change in
treatment practice, may have contributed to the
observed increase in patients aged 40 or older that
requires particular attention. Furthermore, the observed
age trends may be due to the effectiveness of MMT in
decreasing mortality of drug users as compared to those
not in treatment.
The findings also point to another relevant trend
among MMT patients. As compared to 1996, there were
considerably more patients receiving a disability pension
or social welfare benefits in 2003, which also may be a
consequence of this population’s aging and its problems
related to prolonged substance use and associated life-
style, such as comorbidity, malnutrition, loss of work,
unsanitary living conditions, violence, and trauma
[40-42].
Table 1 Socio-demographic and clinical characteristics of the methadone patient population in Basel-City, Switzerland,
1996 and 2003
Variables Sample 1996 (n = 1,195) Sample 2003 (n = 958) Statistical data
Age in years, mean (SD) 30.3 (6.3) 38.0 (7.1) T[1602,7] = 24.39; p < 0.001
Age category Chi2 [3] = 419.32; p < 0.001
20-29 yrs 52.8 12.3
30-39 yrs 39.0 48.9
40-49 yrs 7.8 34.2
> 50 yrs 0.4 4.6
Men 67.7 68.3
Dose in mg, mean (SD) 70.4 (39.9) 80.9 (59.4) T[1213] = 3.71; p < 0.001
Yrs in current treatment, mean (SD) 3.2 (3.2) 8.6 (4.3) T[1296,3] = 29.12; p < 0.001
1-year retention rate 65.4 86.9 Chi2 [1] = 111.13; p < 0.001
Educational level Chi2 [2] = 20.70; p < 0.001
Regular school 56.5 45.4
Apprenticeship 40.2 51.1
Higher education 3.3 3.5
Employment status/source of income Chi2 [2] = 104.55; p < 0.001
Employed (unemployment ins. incl.) 48.9 24.1
Social welfare 24.0 33.9
Disability pension 27.1 42.0
Heroin use in the past month 74.5 47.1 Chi2 [1] = 95.37; p < 0.001
Cocaine use in the past month 36.5 49.6 Chi2 [1] = 13.83; p < 0.001
Values are percentages unless otherwise indicated.
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Among the MMT population of Basel-City, past-
month heroin use decreased significantly through time,
from 74.5% to 47.1%. This could be the result of higher
methadone doses and longer stays in treatment
[13,28,33]. However, past-month cocaine use in this
population increased from 36.5% to 49.6%. This finding
is comparable to that of a study of clients of Swiss nee-
dle-sharing facilities from 1993-2006 [43]. Among other
reasons, this shift from heroin to cocaine use may be
the result of the decreasing price of cocaine [44] or the
declining purity of street heroin which may lose attrac-
tiveness in the light of agonist properties of methadone
received in treatment. New patterns of consumption
have accompanied the shift, with heroin, cocaine and
sometimes rapid-onset benzodiazepines used together
[43]. The sustained increase in cocaine use among
MMT patients contrasts with the relatively constant pre-
valence in the general population [45] and underlines
the increased vulnerability for multiple drug use in this
group.
Treating aging methadone patients
This study confirms trends outlined in previous reports
from the US showing that MMT populations are getting
older with many patients aged 50 and older [18,21]. As
positive as this trend is, the aging of the methadone
population throws up a host of questions. Aging is a
process that brings about changes that can have a pro-
found impact on a person’s health and well-being. The
same applies to methadone patients, and often even
more so, since many of them have aged prematurely as
a result of a history of long-standing substance use [46],
and they often suffer from chronic diseases
[20,23,25,47,48]. Health problems resulting from pro-
longed substance use can accelerate the decline in
health some older persons already experience. Addition-
ally, psychosocial problems, such as diminished relation-
ship webs as well as reduced socioeconomic resources
and security, often follow. Elderly methadone patients
may experience marginalization in the peer group of
substance users and thus suffer from multiple stigmati-
zation due to drug use and age [49,50]. Many reintegra-
tive approaches in treatment of substance users are
based on work or other occupation and may not be sui-
ted for this patient group. On the other hand, elderly
substance users in general have been shown to profit
from psychotherapy and may do so even more when
this is tailored to their needs [51,52]. Depressive disor-
ders may also be overrepresented among older MMT
patients [20,23,25]. However, there has been almost no
research addressing the specific problems and needs of
older methadone patients. Consequently, many ques-
tions about the adequate medical care of these patients
and its cost-effectiveness remain unanswered. Health
care professionals, however, must address the practical
treatment problems of older MMT patients, such as
chronic disease, pain and disability.
From a medical perspective, older MMT patients
should be accorded treatment appropriate to their age,
just like any other patients-meaning methadone should
be considered as a medication for the well-being of
these patients without reservation. The underlying ther-
apeutic approach must be guided by professionalism
and respect, and should be tailored to the individual
patient’s needs. It is also worth taking into account that
many patients have made negative experiences with the
medical system during their substance use history and
have been subject to stigmatization [49]. MMT provi-
ders must develop new approaches as they face a grow-
ing population of older patients who tend to have long
treatment histories, sometimes 30 years or more [3].
Many of them are interested in their health and are
amongst the most stable patients [18,24,53]. However,
state regulations, existing rules and prejudices surround-
ing methadone may affect them and their treatment
[4,54]. In Switzerland as in most other countries, take-
home methadone is subject to regulations which limit
take-home doses to a maximum of a couple of days,
irrespective of duration and course of treatment. Even
though it would be desirable to allow healthy older
patients in stable treatment fewer visits of the treatment
provider, take-home doses are generally limited to a
maximum of one week in Basel.
On the other hand, older patients can also pose a
unique set of clinical challenges related to the medical
issues of aging, such as arthritis, hypertension, liver dis-
ease, obstructive pulmonary disease, osteoporosis, dia-
betes, and reduced mobility [20,22,23,25,55]. Thus, the
cooperation between MMT providers and institutions of
primary as well as secondary care is of growing impor-
tance. And, there can be complications with elderly
patients when they are provided with extended take-
home methadone doses. Some persons may have diffi-
culties handling larger supplies of methadone due to
neurocognitive impairment associated with aging or pro-
longed substance use [56,57], or because they have to
take various other medications. In such cases, it would
be important for MMT providers to work proactively or
to turn to external help systems (e.g. family, relatives,
home care services), which can offer assistance with
medications and activities of daily living. Alternatively,
methadone and other medications could be received
from local primary care physicians or pharmacies under
the direction of specialized clinics, if necessary.
As of yet, there are no proven data on age-related
alterations in methadone metabolism. Methadone dose
adjustments are thus not automatically necessary due to
aging. However, since renal function may decline in the
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elderly, the dose needs to be monitored closely and
adjusted if necessary. As with younger patients, dose
adjustments may be required for patients taking other
medications known to interact with methadone (e.g.
antiviral medications, SSRIs, antiepileptics) or for
patients with severe liver or kidney disease [58-60].
There is some evidence from animal experiments and
treatment of chronic pain patients that opioid tolerance
may develop more slowly with age [61,62]. In any case,
care should be taken when increasing doses at the
beginning of treatment or after omission of provision
days. Due to cumulative effects, caution is needed when
respiratory-depressant medications such as benzodiaze-
pines are prescribed. The same holds true for patients
with excessive alcohol intake or use of respiratory-
depressant drugs [63,64]. Generally, physicians should
aim for prescription of straightforward pharmaceutic
combinations and dosing regimens. Clinical experience
further shows that women going through menopause
may request methadone dose increases. Medical staff as
well as patients should be aware that uncomfortable
perimenopausal symptoms, such as hot flashes, out-
breaks of sweat and fatigue are often identical to opioid
withdrawal symptoms [65-67]. Methadone dose
increases may not always be indicated in these cases.
Standardized assessments of neurocognitive, psychoso-
cial and medical functioning at regular, for example
yearly, intervals may prove helpful in determining the
appropriate level of autonomy and support in the treat-
ment setting for the individual patient.
Future challenges surrounding the care of methadone
patients
As time passes, more methadone patients are going to
require skilled nursing care. However, many health care
services and nursing homes are not equipped to, and
some are not prepared to, care for these patients. The
latter is often based on prejudices that carry over even
to patients who have long stopped using illicit drugs.
The observed increase in cocaine use, however, with a
substantial proportion of elderly patients using the drug
may further contribute to this problematic issue. There
is also still the ill-informed view that older persons who
have lived a long time without taking illicit opioids
should no longer need methadone. Contrary to the
“maturing-out” theory [68], which suggests that opioid-
dependent persons grow out of their substance use dis-
order as they get older, many patients still require
methadone for their well-being as they age [3,69]. Some
older patients may even require higher methadone doses
for reasons of comedication [70]. Others may be resis-
tant to the lowering of their long-standing dosage due
to the fear of withdrawal, even if an adjustment would
be indicated [22,58]. This means methadone providers
are required to raise awareness for this issue and pro-
pose ways of closer cooperation with institutions and
care homes. On the other hand, it is important that
home care providers and skilled nursing facilities be
aware of the issues involved and plan accordingly.
Our study has several limitations. The analysis did not
include all patients registered for MMT in Basel-City.
However, the annual rate of returned questionnaires was
high (>83%) which suggests that the developments out-
lined above closely resemble actual trends. The study
further used a retrospective approach and only consid-
ered a limited amount of information about the MMT
patients of Basel-City and their treatment. It provides,
however, valuable information on certain developments
concerning this population and on changes in treatment
practice. It also helps to optimize MMT services and to
support policy makers and practitioners in decision-
making and treatment planning. Finally, some data
relied on an instrument which depended upon informa-
tion treatment providers had, and not all providers filled
in all questionnaire items.
Conclusions
Despite these limitations, two conclusions can be
drawn from the present findings. First, MMT popula-
tions are getting older, not only in the US but also in
Switzerland and most likely in many other European
countries. Second, MMT practice has changed in the
last decades, which is corroborated by other studies
[71,72] and is most likely owed to research. However,
as positive as these trends are, they will pose chal-
lenges for MMT providers and the entire health care
system in the near term. We would welcome increased
efforts from researchers and practitioners to deal with
this issue. It is time for us to develop resources and to
use them to meet the special needs of this patient
population, and to train staff accordingly. Increased
knowledge about these persons’ needs, and the special
issues involved in their care, will help decrease preju-
dice against them, improve the quality of care, and,
indeed their quality of life.
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